Evidence map›Paper›PMID 32597957›Full record

ArticleNucleic acids research2020

Mechanism of translation inhibition by type II GNAT toxin AtaT2.

Stepan V Ovchinnikov, Dmitry Bikmetov, Alexei Livenskyi, Marina Serebryakova, Brendan Wilcox, Kyle Mangano, Dmitrii I Shiriaev, Ilya A Osterman, Petr V Sergiev, Sergei Borukhov and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Are all VapC toxins ofJournal of biosciences · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Stepan V OvchinnikovCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Dmitry BikmetovCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
Alexei LivenskyiInstitute of Gene Biology, Russian Academy of Science, 119334 Moscow, Russia.
Marina SerebryakovaInstitute of Gene Biology, Russian Academy of Science, 119334 Moscow, Russia.
Brendan WilcoxCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Kyle ManganoCenter for Biomolecular Sciences, University of Illinois, Chicago, IL 60607, USA.
Dmitrii I ShiriaevDepartment of Chemistry, Lomonosov Moscow State University, Moscow 119992, Russia.
Ilya A OstermanCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Petr V SergievCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Sergei BorukhovDepartment of Cell Biology and Neuroscience, Rowan University School of Osteopathic Medicine, Stratford, NJ 08084-1489, USA.
Nora Vazquez-LaslopCenter for Biomolecular Sciences, University of Illinois, Chicago, IL 60607, USA.
Alexander S MankinCenter for Biomolecular Sciences, University of Illinois, Chicago, IL 60607, USA.
Konstantin SeverinovCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Svetlana DubileyCentre for Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.
Skolkovo Institute of Science and Technology · RULomonosov Moscow State University · RUUniversity of Illinois Chicago · USInstitute of Gene Biology · RURowan University · US

Funding

Context-specific action of antibiotics targeting the catalytic center of the bacterial ribosomeR01AI125518 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MANKIN, ALEXANDER S, VAZQUEZ-LASLOP, NORA · 2016 to 2019
$1.6M
NIAID NIH HHS R01 AI125518
6 · The paper itself

Abstract

Type II toxin-antitoxins systems are widespread in prokaryotic genomes. Typically, they comprise two proteins, a toxin, and an antitoxin, encoded by adjacent genes and forming a complex in which the enzymatic activity of the toxin is inhibited. Under stress conditions, the antitoxin is degraded liberating the active toxin. Though thousands of various toxin-antitoxins pairs have been predicted bioinformatically, only a handful has been thoroughly characterized. Here, we describe the AtaT2 toxin from a toxin-antitoxin system from Escherichia coli O157:H7. We show that AtaT2 is the first GNAT (Gcn5-related N-acetyltransferase) toxin that specifically targets charged glycyl tRNA. In vivo, the AtaT2 activity induces ribosome stalling at all four glycyl codons but does not evoke a stringent response. In vitro, AtaT2 acetylates the aminoacyl moiety of isoaccepting glycyl tRNAs, thus precluding their participation in translation. Our study broadens the known target specificity of GNAT toxins beyond the earlier described isoleucine and formyl methionine tRNAs, and suggest that various GNAT toxins may have evolved to specificaly target other if not all individual aminoacyl tRNAs.

Indexed as

AcetyltransferasesAntitoxinsBacterial ToxinsEscherichia coli O157Glycine-tRNA LigaseProtein BiosynthesisToxin-Antitoxin SystemsAcetyltransferasesAntitoxinsBacterial ToxinsGlycine-tRNA Ligase

Identifiers

PMID32597957
PMCPMC7470980
OpenAlexW3038100274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.